



PAUL COHEN'S *Marijuana Hub*

A Division of Cohen Grassroots Research, Inc. www.cohengrassroots.com



Newsletter: March 18, 2015, Issue #114 -- www.cohenresearch.com

Cohen Grassroots Research, Inc. is the Nation's Number #1 Micro Cap and Cannabis Research Firm
IR Research Reports (1,000+) - Distribution to 100s of thousands of investors

HOW TO MAKE MONEY IN THE MARIJUANA STOCK MARKET

MORE ON CANNABIS SCIENCE, INC. CBIS

►Our 115 page IR Research Report on Cannabis Science, Inc. CBIS describes one of the oldest and premier medical cannabis companies in the cannabis/marijuana industry. The medical cannabis industry is here to stay.

►CBIS has a world class scientific advisory Board and compounds in enormous markets. New CEO Ray Dabney has converted CBIS from a biotech company to a revenue producing biotech company. www.cohenresearch.com and www.cohengrassroots.com. The following is quoted:

The Cannabis Science model is similar to a drug development company by creating a cannabinoid portfolio of intellectual property and other trade secrets. To support this research and development portfolio, Cannabis Science is working on creating cannabis-based, cannabinoid medical applications and research for drug development that one day may reach multi-billion dollar markets. The Company is working on designing formulations for possible future treatments for skin cancers. In another area of development, the Company believes cannabinoids can successfully treat drug resistant strains of Kaposi's Sarcoma, a condition presented in many long-term HIV patients. Cannabis Science has plans to formulate a novel approach to directly treat the HIV virus that may have benefits and applications for other infectious diseases. The Company has a need for the continuation of financing, and is actively seeking collaborations with partners to share complimenting models, which can be vertically integrated in research, development and ultimately commercialization.

In a few short months, new CEO and President Mr. Raymond C. Dabney has restructured and redirected the business model, adding revenue producing businesses and expanding the CBIS footprint worldwide. CBIS has a goal to obtain the funding, data, and other resources required to file a pre-investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for one of the properties in its portfolio. The Company also intends to initiate new clinical trials. CBIS continues to focus on financing and collaboration with partners to share synergies in R&D and commercialization. Plans for development of CS-TATI -1 and CS-S/BCC-1 programs are under active investigation. In addition, the Company's new patent-protected CS-NEURO-1 program mission focuses on cannabinoid-based formulations to treat neurological disorders.